WilmerHale represented Dyne Therapeutics, Inc. in transactions securing up to $505 million of debt and equity capital, including a $275 million senior secured debt financing with Hercules Capital, Inc., as agent and lender, and a concurrent $230 million underwritten public offering of common stock. The loan facility consists of a $100 million term loan funded at closing, and four additional contingent term loan tranches totaling up to $175 million. In the underwritten public offering, Dyne Therapeutics issued and sold 27,878,788 shares of its common stock at a public offering price of $8.25 per share, which includes 3,636,363 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.  The loan facility closed on June 27, 2025, and the equity financing closed on July 2, 2025.  Dyne Therapeutics is a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.

The WilmerHale loan facility team consisted of Nathan Moore, George Shuster, Alex Dean and Jamie Wolfe, with paralegal support from Lorri Strizich, and the WilmerHale equity financing team was led by Stuart Falber and Scott Lunin and included Victoria Peluso, Michelle Sidle, Amy O’Connell, Conor Gutierrez and Abi King.